Psiquiatria
M-A | Resposta à monoterapia farmacológica aguda para transtornos depressivos maiores em estudos randomizados e placebo-controlados.
5 Ago, 2022 | 16:48h
M-A | Prevalência de ideação suicida e comportamentos autodestrutivos em crianças de até 12 anos de idade.
2 Ago, 2022 | 13:03hPrevalence of suicidal ideation and self-harm behaviours in children aged 12 years and younger: a systematic review and meta-analysis – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Comentário no Twitter
*New* systematic review & meta-analysis estimates a prevalence of 7·5% for suicidal ideation, 2·2% for suicide planning, 1·4% for self-harm, 1·3% for suicide attempts, & 21·9% for non-suicidal self-injury in children aged ≤12 years
In @TheLancetPsych #childhoodsuicide https://t.co/wFbv6eKpNs
— The Lancet Child & Adolescent Health (@LancetChildAdol) July 28, 2022
Estudo randomizado | Eficácia e segurança da viloxazina em cápsulas de liberação prolongada para adultos com transtorno de déficit de atenção/hiperatividade.
2 Ago, 2022 | 13:01h
Grande estudo observacional sugere que antipsicóticos injetáveis de ação longa estão associados a desfechos melhores do que antipsicóticos orais em pessoas com esquizofrenia.
1 Ago, 2022 | 15:12hComentário convidado: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open
Conteúdos relacionados:
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link para o resumo – $ para o texto completo)
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Comentário no Twitter
This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
M-A | Indicadores socioeconômicos do prognóstico de tratamento para adultos com depressão.
1 Ago, 2022 | 15:06hComunicado de imprensa: People without jobs or secure housing have worse outcomes when treated for depression – University College London
Comentário no Twitter
Socioeconomic disadvantage in employment and housing is associated with considerably worse outcomes in #depression, regardless of treatment type and after adjusting for clinical prognostic factors. https://t.co/bVTQv5zx8C
— JAMA Psychiatry (@JAMAPsych) May 6, 2022
M-A | Vortioxetina para tratamento de transtorno depressivo maior em adultos.
18 Jul, 2022 | 13:07h
Estudo randomizado | Teste farmacogenômico para interações medicamento-genes fornece pouco benefício à remissão de sintomas no transtorno depressivo maior.
18 Jul, 2022 | 13:04hEffect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress – JAMA (gratuito por tempo limitado)
Comentário: Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder? — The evidence is unclear – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
In this randomized clinical trial, pharmacogenomic testing for drug-gene interactions in major depressive disorder reduced prescription of medications with predicted drug-gene interactions but had small and nonpersistent effects on symptom remission. https://t.co/Z2OIK3h1Bo pic.twitter.com/8eKSipfBFN
— JAMA (@JAMA_current) July 12, 2022
Metanálise sugere que a estimulação cerebral pode reduzir os sintomas negativos de esquizofrenia.
13 Jul, 2022 | 12:03hEstudo original: Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia: A Systematic Review and Network Meta-analysis – JAMA Psychiatry (link para o resumo – $ para o texto completo)
Entrevista com o autor: Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia
Revisão | Como avaliar e cuidar do paciente suicida no departamento de emergência.
13 Jul, 2022 | 11:59hHow to evaluate and care for the suicidal patient in the ED – emDocs
Revisão | Anorexia nervosa e o trato gastrintestinal.
12 Jul, 2022 | 11:31hAnorexia nervosa and the gastrointestinal tract – Frontline Gastroenterology (gratuito por tempo limitado)
Comentários no Twitter
Summary of GI manifestations of anorexia nervosa #FGDebate https://t.co/hwsqfBBrr9@GastroNW pic.twitter.com/Mp1IHfpGKc
— Frontline Gastro (@FrontGastro_BMJ) October 13, 2021
Table summary of GI manifestations in anorexia nervosa, including rare symptoms #FGDebate @GastroNW https://t.co/hwsqfBBrr9 pic.twitter.com/Thqj1xKLEj
— Frontline Gastro (@FrontGastro_BMJ) October 13, 2021